HUTCHMED (HCM) Stock Price, News & Analysis

Company Overview

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer. Its clinical pipeline features both small molecules and monoclonal antibodies targeting receptor tyrosine kinases, immuno-oncology checkpoints and novel pathways, with ongoing trials in the United States, Europe and Asia. The company has established strategic partnerships and licensing collaborations with leading global pharmaceutical and biotechnology firms to co-develop and co-commercialize its assets.

Founded in 2000 as Hutchison MediPharma and rebranded as HUTCHMED in 2018, the company is headquartered in Hong Kong, with research and development centers in Shanghai and Suzhou, China. HUTCHMED maintains commercial operations across mainland China and extends its clinical research infrastructure to the United States and Europe. Guided by an experienced leadership team with backgrounds in drug discovery, clinical development and commercial strategy, HUTCHMED continues to pursue its goal of delivering innovative medicines to patients worldwide.

Key Stats

• Today's Range: $14.60 to $15.05
• 50-Day Range: $14.76 to $17.93
• 52-Week Range: $11.51 to $21.25
• Volume: 31,191 shs
• Average Volume: 44,422 shs
• Market Capitalization: $2.57 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.88
• Consensus Rating: Hold

HUTCHMED Stock Analysis - MarketRank™

HUTCHMED scored higher than 57% of companies evaluated by MarketBeat, and ranked 466th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

HUTCHMED has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.

Upside Potential

HUTCHMED has a consensus price target of $20.88, representing about 41.4% upside from its current price of $14.76.

Amount of Analyst Coverage

HUTCHMED has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 812.50%

Earnings Growth

Earnings for HUTCHMED are expected to grow by 812.50% in the coming year, from $0.16 to $1.46 per share.

Price to Book Value per Share Ratio

HUTCHMED has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.21% of the outstanding shares of HUTCHMED have been sold short.

Short Interest Ratio / Days to Cover

HUTCHMED has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in HUTCHMED has recently decreased by 9.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

HUTCHMED does not currently pay a dividend.

Dividend Growth

HUTCHMED does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.21% of the outstanding shares of HUTCHMED have been sold short.

Short Interest Ratio / Days to Cover

HUTCHMED has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in HUTCHMED has recently decreased by 9.91%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.5 / 5
• News Sentiment: 0.77

News Sentiment

HUTCHMED has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for HUTCHMED this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, HUTCHMED insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.60% of the stock of HUTCHMED is held by insiders.

Percentage Held by Institutions

Only 8.82% of the stock of HUTCHMED is held by institutions.

HCM Stock Analysis - Frequently Asked Questions

How have HCM shares performed this year?

HUTCHMED's stock was trading at $14.41 at the beginning of 2025. Since then, HCM stock has increased by 2.4% and is now trading at $14.76.

When did HUTCHMED IPO?

HUTCHMED (HCM) raised $100 million in an IPO on Thursday, March 17th 2016. The company issued 6,100,000 shares at $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities served as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

How do I buy shares of HUTCHMED?

Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some other companies that HUTCHMED investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

• Today: 10/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HCM
• CIK: 1648257
• Web: www.chi-med.com
• Phone: 852-2121-3888
• Fax: 852-2128-1778
• Employees: 1,811
• Year Founded: 2000

Price Target and Rating

• Average Price Target for HUTCHMED: $20.88
• High Price Target: $28.00
• Low Price Target: $13.75
• Potential Upside/Downside: +41.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 4.65
• Quick Ratio: 4.51

Sales & Book Value

• Annual Sales: $602.20 million
• Price / Sales: 4.28
• Cash Flow: $0.28 per share
• Price / Cash Flow: 52.36
• Book Value: $4.43 per share
• Price / Book: 3.33

Miscellaneous

• Outstanding Shares: 174,430,000
• Free Float: 168,151,000
• Market Cap: $2.57 billion
• Optionable: Not Optionable
• Beta: 0.45